2014年以降に当部門より発表した論文（*は corresponding authorを、X timesは 2024年4月1日現在の被引用回数を示す）

1. *Sakuma Y, Hirai S, Sumi T, Niki T, Yamaguchi M. Dual inhibition of KIF11 and BCL2L1 induces apoptosis in lung adenocarcinoma cells. Biochem Biophys Res Commun 2023; 678: 84-9.
2. Yamaguchi M, Hirai S, Idogawa M, Sumi T, Uchida H, Fujitani N, Takahashi M, *Sakuma Y. Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma. Exp Cell Res 2023; 426: 113570. (2 times)
3. Hirai S, Idogawa M, Sumi T, Yamaguchi M, Niki T, *Sakuma Y. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells. Biochem Biophys Res Commun 2022; 630: 24-9. (2 times)
4. Yamaguchi M, Hirai S, Idogawa M, Uchida H, *Sakuma Y. Anthrax toxin receptor 2 is a potential therapeutic target for non-small cell lung carcinoma with MET exon 14 skipping mutations. Exp Cell Res 2022; 413: 113078. (3 times)
5. *Sakuma Y, Hirai S, Sumi T, Tada M, Kojima T, Niki T, Yamaguchi M. MCL1 inhibition enhances the efficacy of docetaxel against airway-derived squamous cell carcinoma cells. Exp Cell Res 2021; 406: 112763. (3 times)
6. Yamaguchi M, Hirai S, Tanaka Y, Sumi T, Tada M, Takahashi H, Watanabe A, *Sakuma Y. Pericyte-myofibroblast transition in the human lung. Biochem Biophys Res Commun 2020; 528: 269-75. (19 times)
7. Hirai S, Tada M, Yamaguchi M, Niki T, *Sakuma Y. EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival. Biochem Biophys Res Commun 2020; 526: 417-23. (6 times)
8. *佐久間裕司. 肺組織に存在する線維芽細胞の由来と病的意義. BIO Clinica 2019; 34: 1230-3.
9. Tada M, Sumi T, Tanaka Y, Hirai S, Yamaguchi M, Miyajima M, Niki T, Takahashi H, Watanabe A, *Sakuma Y. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells. Lung Cancer 2019; 133: 88-95. (9 times)
10. Tanaka Y, Yamaguchi M, Hirai S, Sumi T, Tada M, Saito A, Chiba H, Kojima T, Watanabe A, Takahashi H, *Sakuma Y. Characterization of distal airway stem-like cells expressing N-terminally truncated p63 and thyroid transcription factor-1 in the human lung. Exp Cell Res 2018; 372: 141-9. (16 times)
11. Sumi T, Hirai S, Yamaguchi M, Tanaka Y, Tada M, Niki T, Takahashi H, *Sakuma Y. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells. Biochem Biophys Res Commun 2018; 501: 253-8. (7 times)
12. Sumi T, Hirai S, Yamaguchi M, Tanaka Y, Tada M, Yamada G, Hasegawa T, Miyagi Y, Niki T, Watanabe A, Takahashi H, *Sakuma Y. Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas. Int J Oncol 2018; 53: 33-46. (20 times)
13. *Sakuma Y. Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis. Pathol Int 2017; 67: 379-88. (34 times)
14. Yamaguchi M, Hirai S, Sumi T, Tanaka Y, Tada M, Nishii Y, Hasegawa T, Uchida H, Yamada G, Watanabe A, Takahashi H, *Sakuma Y. Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma. Biochem Biophys Res Commun 2017; 487: 613-8. (14 times)
15. Yamaguchi M, Hirai S, Tanaka Y, Sumi T, Miyajima M, Mishina T, Yamada G, Otsuka M, Hasegawa T, Kojima T, Niki T, Watanabe A, Takahashi H, *Sakuma Y. Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis. Lab Invest 2017; 97: 232-42. (50 times)
16. *Sakuma Y, Nishikiori H, Hirai S, Yamaguchi M, Yamada G, Watanabe A, Hasegawa T, Kojima T, Niki T, Takahashi H. Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype. Lab Invest 2016; 96: 391-8. (21 times)
17. Nishii Y, Yamaguchi M, Kimura Y, Hasegawa T, Aburatani H, Uchida H, Hirata K, *Sakuma Y. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells. Int J Oncol 2015; 46: 1781-7. (18 times)
18. *Yamaguchi M, Nishii Y, Nakamura K, Aoki H, Hirai S, Uchida H, Sakuma Y, Hamada H. Development of a sensitive screening method for selecting monoclonal antibodies to be internalized by cells. Biochem Biophys Res Commun 2014; 454: 600-3. (18 times)

佐久間裕司

2013年以前の主要原著論文（*は corresponding authorを、X timesは 2024年4月1日現在の被引用回数を示す）

1. *Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y, Yokose T, Oguni S, Niki T, Miyagi Y. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest 2013; 93: 1137-46. (44 times)
2. *Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells. Biochem Biophys Res Commun 2012; 423: 667-71. (22 times)
3. *Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Yokose T, Kameda Y, Koizume S, Miyagi Y. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest 2012; 92: 371-83. (41 times)
4. *Sakuma Y, Tsunezumi J, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep 2011; 25: 661-7. (16 times)
5. *Sakuma Y, Takeuchi T, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Ohgane N, Yokose T, Kameda Y, Tsuchiya E, Miyagi Y. Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. J Pathol 2010; 220: 574-85. (18 times)
6. *Sakuma Y, Okamoto N, Saito H, Yamada K, Yokose T, Kiyoshima M, Asato Y, Amemiya R, Saitoh H, Matsukuma S, Yoshihara M, Nakamura Y, Oshita F, Ito H, Nakayama H, Kameda Y, Tsuchiya E, Miyagi Y. A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2cm or less in size. Lung Cancer 2009; 65: 85-90. (7 times)
7. Sakuma Y, Matsukuma S, Yoshihara M, Sakurai S, Nishii M, Kishida T, Kubota Y, Nagashima Y, Inayama Y, Sasaki T, Nakamura Y, Miura T, Kameda Y, Tsuchiya E, *Miyagi Y. Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan. Cancer Lett 2008; 259: 119-26. (16 times)
8. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Nakayama H, Kameda Y, Tsuchiya E, *Miyagi Y. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol 2007; 20: 967-73. (30 times)
9. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, Kameda Y, Tsuchiya E, *Miyagi Y. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: Confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007; 128:100-8. (110 times)
10. Kawanowa K, Sakuma Y, *Sakurai S, Hishima T, Iwasaki Y, Saito K, Hosoya Y, Nakajima T, Funata N. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37: 1527-35. (307 times)
11. Sakuma Y, *Sakurai S, Oguni S, Satoh M, Hironaka M, Saito K. c-kit gene mutations in intracranial germinomas. Cancer Sci 2004; 95: 716-20. (61 times)
12. Sakuma Y, *Sakurai S, Oguni S, Hironaka M, Saito K. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 2003; 94: 486-91. (81 times)

山口美樹

特許出願

• 抗Trop-2抗体
  発明者 山口美樹、加藤和則、濱田洋文、他
  出願番号： PCT/2011/063294, WO2011/155579

論文

1. 山口美樹、濱田洋文
   腫瘍の標的化を目的とした表面抗原の探索とその実用化に向けて
   胆と膵.2011　Vol.32(2):p129-133.
2. Yamaguchi M, Fujihara M, Wakamoto S, Sakai H, Takeoka S, Tsuchida E, Hamada H, Azuma H, Ikeda H.
   Biocompatibility study of hemoglobin vesicles, cellular-type artificial oxygen carriers, with human umbilical cord hematopoietic stem/progenitor cells using an in vitro expansion system.
   ASAIO J. 2009 May-Jun;55(3):200-5.
3. Azuma H, Yamaguchi M, Takahashi D, Fujihara M, Sato S, Kato T, Ikeda H.
   Elevated Ca?+ influx-inducing activity toward mast cells in pretransfusion sera from patients who developed transfusion-related adverse reactions.
   Transfusion. 2009 Aug;49(8):1754-61.
4. Yamaguchi M, Fujihara M, Wakamoto S, Sakai H, Takeoka S, Tsuchida E, Azuma H, Ikeda H.
   Influence of hemoglobin vesicles, cellular-type artificial oxygen carriers, on human umbilical cord blood hematopoietic progenitor cells in vitro.
   J Biomed Mater Res A. 2009 Jan;88(1):34-42.
5. Yamaguchi M, Azuma H, Fujihara M, Hamada H, Ikeda H.
   Generation of a Considerable Number of Functional Mast Cells with a High Basal Level of FcepsilonRI Expression from Cord Blood CD34(+) Cells by Co-culturing Them with Bone Marrow Stromal Cell Line Under Serum-free Conditions.
   Scand J Immunol. 2007 Jun;65(6):581-8.
6. Kawano Y, Kobune M , Yamaguchi M, Nakanura K, Ito Y, Sasaki K, Takahashi S, Nakamura T, Chiba H, Mathunaga T, Azuma H, Ikabuchi K, Ikeda H, Kato J, Niitsu Y, and Hamada H.
   Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells.
   Blood. 2003 Jan; 101: 532-540
7. Yamaguchi M, Hirayama F, Wakamoto S, Fujihara M, Murahashi H, Sato N, Ikebuchi K, Sawada K, Koike T, Kuwabara M, Azuma H, Ikeda H
   Bone marrow stromal cells prepared using AB serum and bFGF for hematopoietic stem cell expansion.
   Transfusion.2002 Jul; 42(7): 921-7.
8. Yamaguchi M, Hirayama F, Murahashi H, Azuma H, Sato N, Miyazaki H, Fukazawa K, Sawada K, Koike T, Kuwabara M, Ikeda I, Ikebuchi K
   Ex vivo expansion of human cord blood primitive hematopoietic progenitors and transplantable stem cells using human primary bone marrow stromal cells and human AB serum.
   Cytotherapy.2002 ?Vol.4(2): 109-18.
9. Yamaguchi M, Hirayama F, Kanai M, Sato N, Fukazawa K, Yamashita K, Sawada K, Koike T, Kuwabara M, Ikeda H, Ikebuchi K.
   Serum-free coculture system for ex vivo expansion of human cord blood primitive progenitors and SCID mouse-reconstituting cells using human bone marrow primary stromal cells.
   Exp Hematol. 2001 Feb;29(2):174-82.
10. Yamaguchi M, Ikebuchi K, Hirayama F, Sato N, Sekiguchi S.
    Cell cycle-dependent change of the adhesive character of CD34+ progenitor cells and their VLA-4 expression
    Rinsho Byori. 1999? May;47(5):439-46. Review. Japanese.
11. Yamaguchi M, Ikebuchi K, Hirayama F, Sato N, Mogi Y, Ohkawara J, Yoshikawa Y, Sawada K, Koike T, Sekiguchi S.
    Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G0/G1 versus S+G2/M phases of the cell cycle.
    Blood. 1998 Aug 1;92(3):842-8.
12. Yamaguchi M, Sawada K, Sato N, Koizumi K, Sekiguchi S, Koike T.
    A rapid nylon-fiber syringe system to deplete CD14+ cells for positive selection of human blood CD34+ cells. Use of immunomagnetic microspheres.
    Bone Marrow Transplant. 1997 Feb;19(4):373-9.